A new Direction- Market is Digesting New Info
Well, overall for the Nerds this is great news but there is a bit of confusion to clear out.
For the investors / market, check point inhibitors are out. The are pros and cons. Pros = makes the PIII easier, cheaper and faster. There is also less science to manage here. Cons = well ONCY has being selling itself as a value adding checkpoint inhibitor additional option. All these checkpoint inhibitors are out as partners/acquirors. That finally explain why 90 exclusivity period yielded nothing.
Ok, well bottom line. PIII trial could only cost 60$ million and Adlai agreement would pretty much pay for it...
A new list of acquirer/buyers are here. Most of them are the same players but now for different reasons.
It shows how virus killing oncolytic science is still very early.
ONCY probably averted a disastrous PIII if they had not done Bracelet-1. So, kudos on the prudent long approach. It starting to pay off.
Market is confused. It will setllte down. If FDA gives ONCY a notch of agreement, we rocket much higherl. KOL is a good indicator as to how FDA would react. Both have the same kind of expert.
Geeez about the discontinuation... Geeez whizzz they could have reduced to below 27% if they had given more tylenol to people and told them. Well, fever is not a sign of imminent death, bear with it please as the virus activate your immune system... Informing the patient is simple terms goes a long way.
PIII looks not just good but great.
Adlai Nortye remains the most likely acquirer. China wants to be first in any new field. Getting a the advantage in virus oncology makes a lot strategic sense.